Pharmaceutical Product Launch: Why Most Fail Before Launch Day

A pharmaceutical product launch is one of the most commercially complex go-to-market challenges in any industry. You have a narrow window, a heavily regulated environment, a fragmented audience of prescribers, payers, and patients, and a product that often took a decade and hundreds of millions of dollars to reach market. Getting the marketing wrong is not a minor inefficiency. It is a catastrophic waste of that investment.

Most pharma launches underperform not because the science is weak, but because the commercial strategy is built too late, too narrowly, or on assumptions that were never properly tested. The fix is not a bigger budget. It is better thinking, applied earlier.

I have worked across more than 30 industries over two decades, and regulated sectors consistently expose the same gap: companies that are operationally excellent at getting a product approved, but commercially underprepared for what happens next. Pharma is the sharpest version of that problem.

Why Pharmaceutical Launches Are Structurally Different From Other Product Launches

Most product launches in consumer or B2B markets involve a relatively direct relationship between marketing and the buyer. In pharma, that relationship is mediated by at least three distinct stakeholder groups, each with different motivations, different information needs, and different points of influence over the final prescribing decision.

Healthcare professionals (HCPs) need clinical evidence and peer validation. Payers need health economic data and comparative effectiveness arguments. Patients need clarity, reassurance, and often, help advocating for access. These are not variations of the same message. They are fundamentally different commercial conversations, and conflating them is one of the most common and expensive mistakes I see in launch planning.

The regulatory environment adds another layer. Every claim must be substantiated. Every channel has compliance implications. Every piece of promotional material goes through medical, legal, and regulatory review. This is not a constraint to work around. It is a structural reality that has to be built into the timeline and the strategy from the start, not bolted on at the end.

If you are thinking through your broader go-to-market approach, the articles in the Go-To-Market and Growth Strategy hub cover the commercial frameworks that underpin this kind of multi-stakeholder launch planning.

BCG’s analysis of biopharma product launches found that the gap between top-performing and average launches is significant, and that the differentiating factors are almost always commercial and strategic rather than clinical. The science gets you to market. The strategy determines what happens when you get there.

What Does Pre-Launch Market Shaping Actually Mean?

Market shaping is the phase of launch activity that happens before the product is approved. It is also the phase that most companies either compress or skip entirely when timelines get tight. That is a mistake with compounding consequences.

Done properly, pre-launch market shaping involves three things. First, establishing the disease or condition in the minds of prescribers and payers as a priority worth treating differently. Second, positioning your product’s mechanism or approach as the logical next step in that treatment pathway. Third, building the relationships and infrastructure that will carry the launch message when approval comes.

I ran a campaign at lastminute.com that generated six figures of revenue within roughly 24 hours from a relatively simple paid search setup. The reason it worked was not the campaign itself. It was that the audience was already primed, the intent was already there, and the infrastructure was ready to convert it. Pre-launch in pharma serves the same function. You are not selling yet. You are creating the conditions in which selling becomes easier.

For rare diseases or first-in-class therapies, this is especially critical. If prescribers are not diagnosing the condition, or if payers have no framework for evaluating the therapy, you will spend your entire launch budget educating the market rather than converting it. That education needs to happen earlier, and it needs to be funded separately from the promotional launch budget.

How Do You Build a Messaging Architecture Across Multiple Stakeholders?

The instinct in most launch teams is to develop a core brand message and then adapt it for each audience. That logic is understandable and almost always produces weak results. An HCP reading a clinical journal and a payer reviewing a formulary submission are not looking for different versions of the same thing. They are looking for entirely different things.

The messaging architecture for a pharmaceutical launch needs to be built from the audience backwards, not from the brand outwards. Start with what each stakeholder group needs to believe in order to act in your favour. Then build the evidence and the narrative that gets them there. The brand story sits above all of this as a unifying framework, but it should never constrain the specificity of what each audience receives.

For HCPs, the primary currency is clinical credibility. Peer-reviewed data, key opinion leader endorsement, mechanism of action clarity, and comparative efficacy against standard of care. For payers, it is cost-effectiveness, outcomes data, and a clear argument for why this therapy belongs on the formulary at a price point that reflects its value. For patients, it is accessibility, comprehension, and confidence that the therapy is right for them and that they can get it.

This is a lesson that translates well beyond pharma. When I was building out the marketing function at a B2B agency, we had clients who wanted one campaign to do everything: generate awareness, drive consideration, and close the sale. The result was always a campaign that did none of those things particularly well. Specificity is not a luxury. It is a commercial requirement. The same logic applies to how we approach B2B financial services marketing, where regulated environments demand equally precise audience segmentation.

Which Channels Actually Work for HCP Engagement at Launch?

This is where a lot of pharma marketing teams get into trouble. They default to either the traditional model, which is field sales force and medical education events, or they overcorrect into broad digital channels that reach a general audience rather than the specific prescribers they need to influence.

The answer is neither extreme. It is a deliberately constructed channel mix that reflects how your target HCPs actually consume information in their clinical practice. And that requires research, not assumption.

Endemic advertising, which places your message in the professional environments where HCPs are already reading and learning, consistently outperforms broad digital reach for specialist prescriber audiences. A cardiologist reading a cardiology journal online, or a haematologist on a specialist clinical platform, is in a completely different mindset than the same person scrolling a general news feed. The context changes everything about how the message lands.

Forrester’s research on healthcare go-to-market challenges highlights that reaching HCPs through the right professional context is consistently underinvested relative to its impact. The field force remains important, particularly for high-touch specialist relationships, but digital endemic channels now carry a disproportionate share of the early awareness and education work.

Peer-to-peer influence also matters more in medicine than in almost any other sector. Key opinion leaders are not just spokespeople. They are credibility infrastructure. Their adoption signals to the broader prescriber community that a therapy has earned its place. Building those relationships before launch, through advisory boards, investigator-initiated studies, and medical education, is not a nice-to-have. It is a core commercial investment.

What Does Launch Readiness Actually Look Like in Practice?

Launch readiness is a phrase that gets used a lot and defined precisely almost never. In my experience, it means three things are true at the same time: your commercial infrastructure is ready to execute, your digital presence is built to support the commercial conversation, and your internal teams are aligned on what success looks like in the first 90 days.

On the infrastructure side, this means field force trained and deployed, medical affairs ready to respond to clinical queries, market access teams engaged with payers, and patient support programmes live. Any one of these being late creates friction that costs you prescriptions in the window that matters most.

On the digital side, I always recommend running a proper audit of the brand’s web presence before launch. Not just a design review, but a commercial assessment of whether the digital touchpoints are doing the job they need to do for each audience. A structured checklist for analysing your website against your sales and marketing strategy is a useful starting point, particularly for brands that have built their site around regulatory compliance rather than commercial performance.

On internal alignment, this is the one that gets overlooked most often. I have seen launches where the marketing team, the medical affairs team, and the sales force were essentially running three different strategies with three different definitions of the target patient. The result was a confused message in the market and a lot of internal friction that slowed everything down. Alignment on the commercial strategy has to happen before launch day, not during it.

Before committing significant budget to any launch channel, it is also worth conducting proper digital marketing due diligence to understand what the competitive digital landscape looks like, where the gaps are, and whether your planned investment is proportionate to the opportunity.

How Should You Handle Payer and Market Access Strategy?

Market access is not a post-approval problem. It is a pre-launch commercial strategy. If payers are not ready to reimburse your product when prescribers start writing, you have a launch that generates demand you cannot fulfil. That is one of the most demoralising and commercially damaging situations a launch team can face.

The health economics and outcomes research (HEOR) work needs to be developed in parallel with the clinical programme, not after it. Payers want to see comparative effectiveness data, budget impact models, and real-world evidence that the therapy delivers value at the price being asked. Building that case takes time, and it needs to be built to the specific requirements of each payer market, because those requirements vary significantly by country and even by region within countries.

The market access conversation is also a relationship, not a submission. The most effective market access teams I have seen treat payer engagement as an ongoing dialogue, not a one-time negotiation. They understand the payer’s pressures, their budget constraints, their formulary decision timelines, and they build the commercial case around those realities rather than simply presenting the clinical data and expecting a favourable outcome.

There are useful parallels here with how complex B2B sales cycles work in other regulated sectors. The frameworks used in corporate and business unit marketing for B2B technology companies around multi-stakeholder engagement and long sales cycles translate surprisingly well to the payer engagement challenge in pharma.

What Role Does Patient Marketing Play in a Pharma Launch?

Patient marketing in pharma operates under significant regulatory constraints, particularly in markets like the UK and most of Europe where direct-to-consumer advertising of prescription medicines is prohibited. But even within those constraints, there is substantial and underutilised opportunity to support patients in ways that improve outcomes and drive appropriate therapy uptake.

Disease awareness campaigns, patient advocacy partnerships, and condition-specific digital content can all be executed compliantly and can meaningfully influence the patient’s experience from symptom recognition to diagnosis to treatment. what matters is that these programmes need to be designed with the patient’s actual information needs at the centre, not as a workaround for promotional restrictions.

Patient support programmes are another area where the commercial and the ethical align well. A patient who understands their condition, adheres to their therapy, and has support when they encounter side effects or access barriers is both a better health outcome and a better commercial outcome. The brands that invest properly in patient support consistently outperform those that treat it as a compliance requirement rather than a commercial asset.

For brands exploring performance-based models to support patient-facing commercial activity, particularly in markets where direct engagement is possible, pay-per-appointment lead generation models offer an interesting framework for connecting patients with specialist consultations in a cost-efficient, measurable way.

How Do You Measure Launch Performance Without Waiting for Sales Data?

Sales data in pharma lags. Prescription data comes through with a delay. Formulary wins take months to reflect in volume. If you wait for sales data to tell you whether your launch is working, you will be making strategic decisions based on information that is already several months old. By then, the window to course-correct has often closed.

The brands that manage launches well build a leading indicator dashboard that gives them a read on commercial momentum before it shows up in sales. This includes HCP awareness and message recall metrics from market research, share of voice in endemic digital channels, field force activity rates and call quality scores, payer engagement milestones, and patient support programme enrolment rates.

None of these are perfect proxies for sales. But together they give you a directional read on whether the commercial engine is building momentum or stalling. And they give you the ability to make adjustments in weeks rather than quarters.

I spent years working with performance marketing data across multiple industries and the lesson that keeps repeating itself is this: the measurement system you build shapes the decisions you make. If you only measure what is easy to measure, you will optimise for the wrong things. Pharma launch teams that only track sales data end up making reactive decisions. The ones that build a broader indicator set make proactive ones.

Vidyard’s analysis of why go-to-market feels harder than it used to makes the point that the complexity of modern buyer journeys means single-metric measurement is almost always misleading. That observation applies as much to a pharmaceutical launch as it does to a SaaS product.

What Separates the Launches That Win From the Ones That Stall?

I have thought about this question a lot, particularly after working with clients across regulated and complex commercial environments. The answer is not resources. Well-funded launches fail all the time. It is not the quality of the clinical data either, though that obviously matters. The separating factor is almost always the quality of the commercial thinking that went into the strategy before anyone started executing.

The launches that win tend to share a few characteristics. They started their commercial planning earlier than felt necessary. They invested in understanding their target prescribers and payers at a level of specificity that most teams find uncomfortable. They built their messaging architecture from the audience backwards. They treated launch day as a milestone in a longer commercial programme, not as the finish line. And they had the discipline to measure what mattered rather than what was easy.

Early in my agency career, I was handed a whiteboard pen mid-brainstorm when the founder had to leave for a client meeting. The brief was for a major drinks brand, the room was full of experienced people, and the expectation was that I would hold the session together. The instinct was to play it safe and facilitate a process. What actually worked was asking a sharper question than the one we had been given. The same instinct applies to pharmaceutical launch strategy. The brief you are handed is rarely the right brief. The best commercial thinking starts by questioning the assumptions underneath it.

Market penetration strategy frameworks are worth revisiting when you are planning a launch into an established therapeutic category. Understanding the ceiling of the addressable market and the realistic penetration trajectory helps set commercial expectations that are grounded in market reality rather than optimism.

For a deeper look at the broader strategic frameworks that underpin this kind of commercially grounded launch planning, the Go-To-Market and Growth Strategy hub brings together the thinking that connects pre-launch strategy to long-term commercial performance across complex markets.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions